Press releases

Share conversion in RaySearch Laboratories AB (publ)

During March 2018, 200,000 Class A shares were converted to Class B shares, at the request of a shareholder. The total number of votes in RaySearch thereafter amounts to 110,377,548 votes. The total number of registered shares in RaySearch amounts to 34,282,773 shares, out of which 8,454,975 are Class A shares and 25,827,798 are Class B shares.

According to RaySearch Laboratories AB’s (publ) Articles of Association, owners of Class A shares have the right to have such shares converted to Class B shares. A conversion reduces the number of votes in the company. When a conversion has been carried out, RaySearch is obligated by law to disclose information on changes resulting from the conversion.

About RaySearch

RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company has now launched the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

To learn more about RaySearch, go to:

* Subject to regulatory clearance in some markets.

For further information, please contact:

Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)8-510 530 00

This information is information that RaySearch Laboratories AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 08.30 CET on 29 March 2018.